GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies
GLP1 ‐ 1RAs verbessern Gehstrecke und senken Amputation bei Menschen mit Typ-2-Diabetes und peripherer arterieller Verschlusskrankheit: systematische Übersicht und Metaanalyse von randomisierten kontrollierten Studien und Kohortenstudien
Diabetes, Obesity and Metabolism · 2026-04 · 28 (4) · 2775-2783
DOI: 10.1111/dom.70454 ↗Auf einen Blick
Die Metaanalyse zeigt bei Typ-2-Diabetes und PAD eine bessere Gehstrecke unter GLP-1RAs. In Kohortenstudien war das Amputationsrisiko geringer.
Fragestellung
Welche Wirkung haben GLP-1RAs auf funktionelle Gehstrecke, MALE und LEA bei Menschen mit Typ-2-Diabetes und PAD?
Methode
Systematische Übersicht und Metaanalyse von RCTs und Kohortenstudien; Suche bis 10. Oktober 2025; Pooling mit Random-effects-Modell; Bewertung mit RoB2, ROBINS-I und GRADE.
Ergebnisse
7 Studien (3 RCTs, 4 Kohorten) mit 107 092 Teilnehmenden. Gehstrecke: HR 1,10 (95 %-KI 1,05–1,15) in 2 RCTs mit 847 Teilnehmenden. LEA: RR 0,53 (95 %-KI 0,39–0,73) in 4 Kohorten mit 104 292 Teilnehmenden.
Einschränkungen
Für LEA hohe Heterogenität (I 2 = 85,96 %), ganz auf eine Studie zurückzuführen. Weitere RCTs sind laut Autor:innen nötig.
Schlussfolgerung der Autor:innen
GLP-1RAs waren mit einer besseren funktionellen Gehstrecke und einem geringeren Risiko für LEA bei Menschen mit Typ-2-Diabetes und PAD assoziiert.
Kernaussagen
- Gehstrecke verbessert: HR 1,10 (95 %-KI 1,05–1,15)
- LEA geringer in Kohorten: RR 0,53 (95 %-KI 0,39–0,73)
- Weitere RCTs zur Bestätigung der limbenspezifischen Effekte nötig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.01.2026. Verfasst von Dario Giugliano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Peripheral Arterial Disease, Amputation, Surgical, Walking. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The aim of this systematic review and meta‐analysis was to evaluate the effect of GLP‐1RAs on functional walking distance and the risk of major adverse limb events (MALE) or lower extremity amputation (LEA) in people with type 2 diabetes and peripheral artery disease (PAD). Materials and Methods We searched many electronic databases up to 10 October 2025 for randomised controlled trials (RCTs) and cohort studies. We included studies enrolling adults with type 2 diabetes and PAD, comparing GLP‐1RAs against placebo or other glucose‐lowering drugs. The primary outcomes were walking distance, MALE, or LEA. Data were pooled using a random‐effects model, with hazard ratios (HR) or risk ratios (RR). Risk of bias was assessed using RoB2 for RCTs and ROBINS‐I for cohort studies; evidence certainty was evaluated using the GRADE approach.
Results
We included seven studies (3 RCTs, 4 cohorts) enrolling 107 092 participants. The meta‐analysis of two RCTs with 847 participants demonstrated a significant improvement in walking distance with liraglutide or semaglutide (HR = 1.10, 95% CI 1.05–1.15, p < 0.001), with no heterogeneity (I 2 = 0.0%) and moderate certainty of evidence. In the additional meta‐analysis of two RCTs with 3592 participants, the incidence of MALE or LEA did not differ significantly between patients receiving exenatide or semaglutide and those receiving placebo. The meta‐analysis of four cohort studies with 104 292 participants showed that GLP‐1RAs reduced the risk of LEA (RR = 0.53, 95% CI 0.39–0.73, p < 0.001), with high heterogeneity (I 2 = 85.96%), totally related to one study, and very low certainty of evidence. Subgroup analyses showed a significant difference ( p < 0.001) between GLP‐1RA therapies, with the strongest associations with LEA reduction for tirzepatide and semaglutide (55% and 54% risk reduction, respectively); there was no difference in the LEA outcome excluding from the analysis patients with type 2 diabetes and diabetic foot ulcers at baseline.
Conclusions
This meta‐analysis suggests that GLP‐1RAs are associated with a significant improvement in functional walking distance and a reduction in the risk of LEA in people with type 2 and PAD. Further dedicated RCTs are needed to confirm these limb‐specific benefits of GLP‐1RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.
- PhD Program of Translational Medicine, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Division of Endocrinology and Metabolic Diseases, University Hospital, University of Campania "Luigi Vanvitelli", Naples, Italy.
ORCID-Profile: Dario Giugliano, Miriam Longo, Nicole Di Martino, Lorenzo Scappaticcio, Paola Caruso, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito
Zitieren
APA
Giugliano, D., Longo, M., Di Martino, N., Scappaticcio, L., Caruso, P., Bellastella, G., Maiorino, M. I., & Esposito, K. (2026). GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies. Diabetes, Obesity and Metabolism, 28(4), 2775-2783. https://doi.org/10.1111/dom.70454
Vancouver
Giugliano D, Longo M, Di Martino N, Scappaticcio L, Caruso P, Bellastella G, et al. GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies. Diabetes, Obesity and Metabolism. 2026;28(4):2775-2783. doi:10.1111/dom.70454
BibTeX
@article{Giugliano2026,
author = {Giugliano, Dario and Longo, Miriam and Di Martino, Nicole and Scappaticcio, Lorenzo and Caruso, Paola and Bellastella, Giuseppe and Maiorino, Maria Ida and Esposito, Katherine},
title = {GLP1 ‐ 1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {4},
pages = {2775--2783},
doi = {10.1111/dom.70454}
}
EUVIMED